ATLANTA (Reuters Health) Mar 19 – Results of an observational study based on analysis of insurance claims indicate that use of glitazones to manage type 2 diabetes is associated with a significant increase in risk for heart failure. The results were reported here Tuesday morning at the American College of Cardiology 51st Annual Scientific Session.
Dr. Thomas Delea, of Policy Analysis Inc. in Brookline, Massachusetts, used a database that included claims from 35 health insurers who cover up to 17 Americans. A review of claims filed from the period January 1995 to March 2001 identified 8288 diabetics who were treated with troglitazone, rosiglitazone, or pioglitazone and 41,440 diabetic patients who did not use glitazones. Patients who were diagnosed with heart failure in the 12 months prior to the initial claim for a glitazone were excluded from the study.
The initial claim for a glitazone served as the index date. During an average followup from index date of 8.5 months, the risk for heart failure was "4.5% among glitazone users and 2.6% in nonusers," Dr. Delea said at a press briefing on the study. After adjusting for other potential confounders, the use of glitazones was associated with a relative hazard of 1.51 for heart failure (p < 0.001).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!